The M&A fever in the healthcare sector seems to never end: indeed, another important deal has been announced today. Delaware, US-based Alexion Pharmaceuticals has announced, before trading started, that it has acquired Sweden-based Wilson Therapeutics AB for $855m (SEK7.1bn). Alexion has valued the company SEK232 per share, that is to say a premium 70% over yesterday’s closing price (Stockholm) and a 373% premium over the company’s IPO (May 12th 2016). Wilson Therapeutics’ main asset is WTX101, an investigational therapy already tested in a Phase-II clinical trial in patients with the rare Wilson disease–20,000 patients in the EU and US–which is currently undergoing a Phase III clinical trial. WTX101 acts as a binding agent for free copper–which causes the disease–by binding it to a protein, which promotes its removal from the liver. Wilson’s shares have risen 69% today, while Alexion’s have been in a flat trend in pre-market trading. M&A deals for a total value of $650bn (Thomson Reuters) have been announced in the Healthcare sector since the beginning of the year. This figure exceeds the whole year transaction volume registered in 2017, that was approximately $500bn.